HTR1D regulates the PI3K/Akt signaling pathway to impact hepatocellular carcinoma development and resistance to sorafenib

Author:

Zhang Yingai1,Zhang Yuting1,Zhou Shuai2,Rehman Mujeeb Ur1,Lin Fankai2,Zhang Jianquan2,Zhou Hailong1

Affiliation:

1. Hainan University

2. Affiliated Haikou Hospital of Xiangya Medical College, Central South University

Abstract

Abstract

Background Hepatocellular carcinoma (HCC) is a form of cancer with high incidence rates and low survival rates worldwide. Oral sorafenib is a promising therapy for advanced HCC, but resistance to the drug limits its effectiveness. HTR1D, a gene that is highly expressed in HCC, plays a crucial role in the development, drug resistance, and prognosis of the disease.Methods Firstly, the correlation between HTR1D and hepatocellular carcinoma was analyzed by TCGA database, and the expression level of HTR1D in clinical samples was detected by qPCR. Then the siRNA was transfected into HuH-7 and HEP3B cells, and the cell proliferation ability, colony formation ability, migration and invasion ability were detected with or without sorafenib. And the expression of PI3K/Akt pathway was detected by Western Blot. Finally, the potential of HTR1D as a predictive marker for patient prognosis was evaluated by immunohistochemistryResults Analysis of TCGA data showed that methylation of the HTR1D gene was associated with cancer status. Clinical samples confirmed significant differences in HTR1D expression between HCC and adjacent tissues, with higher expression correlating with poorer patient prognosis. Interference with HTR1D gene expression demonstrated its role in promoting HCC proliferation, migration, and drug resistance through the PI3K/Akt pathway. These findings were validated in a mouse model. Immunohistochemical analysis of clinicopathological samples suggested HTR1D could be a valuable prognostic marker for HCC.Conclusion HTR1D is highly expressed in hepatocellular carcinoma tissues, and it can influence hepatocellular carcinoma development and resistance to sorafenib by regulating the PI3K/Akt signaling pathway. In addition, HTR1D has potential as a prognostic indicator.

Publisher

Research Square Platform LLC

Reference21 articles.

1. Treatment of Liver Cancer;Liu CY;Cold Spring Harbor Perspect Med,2015

2. Advances in the early diagnosis of hepatocellular carcinoma;Wang W;Genes Dis,2020

3. Challenges in liver cancer and possible treatment approaches;Anwanwan D;Biochim et Biophys acta Reviews cancer,2020

4. Evolving therapeutic landscape of advanced hepatocellular carcinoma;Yang C;Nat reviews Gastroenterol Hepatol,2023

5. A global view of hepatocellular carcinoma: trends, risk, prevention and management;Yang JD;Nat reviews Gastroenterol Hepatol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3